Stock Analysis
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis
Madrigal Pharmaceuticals, Inc. (MDGL) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Madrigal Pharmaceuticals, Inc. (MDGL) currently has an AIQ Score of 57/100, indicating a neutral setup. Quality is the strongest factor at 67/100. Momentum is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
MDGL at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $427.39 |
| AIQ Score | 57/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $12.5B |
| P/E Ratio (TTM) | -72.32 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $1.90 |
| Revenue (Q3 FY2026) | $431.27M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.41 |
| Volume | 441.25K |
| 52-week range | $353.54-$615.00 |
| RSI 14 | 42.45 |
| 50-Day SMA | $475.72 |
| 200-Day SMA | $496.00 |
| Analyst Price Target | $660.50 |
| Next Earnings | Feb 18, 2027 |
MDGLMadrigal Pharmaceuticals, Inc.
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum40
- Value66
- Quality67
- Risk resilience63
- Sentiment—
MDGL Stock Analysis Summary
Madrigal Pharmaceuticals, Inc. (MDGL) currently has an AIQ Score of 57/100, indicating a neutral setup. Quality is the strongest factor at 67/100. Momentum is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, MDGL has AIQ Score of 57/100 with Quality base of 67/100 and fading Momentum at 40/100. Wait for component alignment before adding exposure.
Quality (67/100) leads while Momentum (40/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.51% stock move · MDGL classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is MDGL Bullish or Bearish Right Now?
MDGL currently has a neutral overall setup. Quality is the strongest factor at 67/100, while Momentum is weakest at 40/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 67/100.
- - Analyst target implies +54.54% upside from the latest quote.
- - Momentum is weak at 40/100.
- - Price is -13.83% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (25 vs 14).
Current Consensus
MDGL's Technical Analysis Consensus is currently Sell, with 14 buy, 7 neutral, and 25 sell votes. MDGL's 14-day RSI is 42.45, which places the stock in a weaker momentum range. MDGL's beta is 0.41, indicating lower market sensitivity than the broad market.
What Changed in MDGL?
The largest recent change in MDGL is Momentum moving down by 1.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the MDGL Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
MDGL Decision Framework
Public evidence layers, setup checks, and risk context for Madrigal Pharmaceuticals, Inc..
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis
Madrigal Pharmaceuticals, Inc. has an AIQ Score of 57/100 in a Neutral regime. Quality is strongest at 67/100. Beta is 0.41, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | MDGL is in a Neutral AIQ regime with score 57/100. |
| Signal Conflict | The primary conflict is that quality leads at 67/100 while momentum lags at 40/100. |
| Factor Evidence | Momentum 40/100 · Value 66/100 · Quality 67/100 · Risk 63/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 67/100.
Momentum is 40/100 and RSI (14) is 42.5.
MDGL is in a Neutral regime at 57/100.
Risk factor is 63/100 with beta 0.41 and annual volatility 42.57%.
Current conflict: quality leads at 67/100 while momentum lags at 40/100.
MDGL Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
MDGL Fundamentals
MDGL valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
MDGL Technical Analysis
MDGL technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
MDGL Stock Catalysts
Track MDGL earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
MDGL Dividend Analysis
MDGL dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
MDGL Financial Data
MDGL revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
MDGL Risk Analysis
MDGL volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
MDGL Stock News
MDGL stock news, market tone, recent headlines, and catalyst context.
MDGL vs Biotechnology Peers
Current peer cohort: MDGL · MIRM · MLYS · NAMS · NBIX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| MDGL Current stock | 57/100 | 66/100 | 40/100 | 63/100 | -0.32 | 42.57% | Current |
| MIRM Mirum Pharmaceuticals, Inc. | 53/100 | 57/100 | 54/100 | 51/100 | 0.79 | 48.60% | MDGL vs MIRM |
| MLYS Mineralys Therapeutics, Inc. | 33/100 | — | 23/100 | 35/100 | -1.48 | 61.66% | MDGL vs MLYS |
| NAMS NewAmsterdam Pharma Company N.V. | 41/100 | 42/100 | 22/100 | 48/100 | -0.91 | 53.82% | MDGL vs NAMS |
| NBIX Neurocrine Biosciences, Inc. | 74/100 | 77/100 | 70/100 | 69/100 | 0.49 | 35.22% | MDGL vs NBIX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for MDGL: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching MDGL
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for MDGL
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
MDGL Stock FAQ
What is MDGL stock price today?
Madrigal Pharmaceuticals, Inc.'s current stock price is $427.39. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is MDGL bullish or bearish right now?
MDGL's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is MDGL's market cap?
MDGL's market cap is $12.5B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is MDGL's current P/E ratio?
MDGL's current P/E ratio is -72.32 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is MDGL's RSI?
MDGL's 14-day RSI is 42.45 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is MDGL above its 50-day and 200-day moving averages?
MDGL is -10.16% from its 50-day SMA and -13.83% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is MDGL's next earnings date?
MDGL's next earnings date is currently listed as Feb 18, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does MDGL pay a dividend?
MDGL's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.